Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer

Wei,Xinghua; Zeng,Weiwei; Xie,Keji; Diao,Pengfei; Tang,Ping

doi:10.3892/ol.2018.7936

Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer

Authors:
- Xinghua Wei
- Weiwei Zeng
- Keji Xie
- Pengfei Diao
- Ping Tang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R. China, Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
Published online on: February 2, 2018 https://doi.org/10.3892/ol.2018.7936
Pages: 5149-5154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although it is the most widely used biomarker for prostate cancer, the use of prostate specific antigen (PSA) is controversial due to its limitations in specificity and sensitivity. The proteasome is a complex associated with cell proliferation and apoptosis, and the abnormity of these processes may lead to tumor occurrence. Previous studies have reported that proteasomal activity is associated with cancer progression and can be used in risk stratification. The purpose of the present study was thus to investigate the feasibility of proteasome activity as a biomarker for prostate cancer. Proteasome activity in vitro and in vivo was detected, along with the expression of the substrate proteins NF‑κB inhibitor‑α (IκB‑α), Bcl-2‑associated X (Bax) and p27. Chymotrypsin‑like proteasomal activity was elevated by 70% in vitro and 23% in vivo, and the expression levels of the proteasome substrate proteins IκB‑α, Bax and p27 were decreased in prostate cancer cells and prostate tumor xenografts compared with normal mouse prostate tissue. In conclusion, proteasomal chymotrypsin‑like activity maybe a potential biomarker for prostate cancer, and may be suitable to supplement PSA in clinical application for prostate cancer diagnosis.

View Figures

View References

1	Saini S: PSA and beyond: Alternative prostate cancer biomarkers. Cell Oncol (Dordr). 39:97–106. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Lei T, Mao WM, Yang HJ, Chen XZ, Lei TH, Wang XH, Ying Q, Chen WQ and Zhang SW: Study on cancer incidence through the cancer registry program in 11 cities and counties, China. Zhonghua Liu Xing Bing Xue Za Zhi. 30:1165–1170. 2009.(In Chinese). PubMed/NCBI
4	Fong MK, Hare R and Jarkowski A: A new era for castrate resistant prostate cancer: A treatment review and update. J Oncol Pharm Pract. 18:343–354. 2012. View Article : Google Scholar : PubMed/NCBI
5	Rodrigues DN, Butler LM, Estelles DL and de Bono JS: Molecular pathology and prostate cancer therapeutics: From biology to bedside. J Pathol. 232:178–184. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lilja H: Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer. Clin Chem. 54:1248–1249. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 8:268–278. 2008. View Article : Google Scholar : PubMed/NCBI
8	Romero Otero J, Garcia Gomez B, Campos Juanatey F and Touijer KA: Prostate cancer biomarkers: An update. Urol Oncol. 32:252–260. 2014. View Article : Google Scholar : PubMed/NCBI
9	Cary KC and Cooperberg MR: Biomarkers in prostate cancer surveillance and screening: Past, present, and future. Ther Adv Urol. 5:318–329. 2013. View Article : Google Scholar : PubMed/NCBI
10	Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
11	Voorhees PM, Dees EC, O'Neil B and Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 9:6316–6325. 2003.PubMed/NCBI
12	Ciechanover A: The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J. 17:7151–7160. 1998. View Article : Google Scholar : PubMed/NCBI
13	Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP and Meunier L: High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol. 152:948–953. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009. View Article : Google Scholar : PubMed/NCBI
15	Piantanelli L, Zaia A, Rossolini G, Piantanelli A, Basso A and Anisimov VN: Long-live euthymic BALB/c-nu mice. I. Survival study suggests body weight as a life span predictor. Mech Ageing Dev. 122:463–475. 2001. View Article : Google Scholar : PubMed/NCBI
16	An B, Goldfarb RH, Siman R and Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1062–1075. 1998. View Article : Google Scholar : PubMed/NCBI
17	Harmelin A, Danon T, Kela I and Brenner O: Biopsy of the mouse prostate. Lab Anim. 39:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wada M, Kosaka M, Saito S, Sano T, Tanaka K and Ichihara A: Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med. 121:215–223. 1993.PubMed/NCBI
19	Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF and Bureau JP: Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer. 92:2493–2500. 2001. View Article : Google Scholar : PubMed/NCBI
20	Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP and Ouali A: Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods. 260:183–193. 2002. View Article : Google Scholar : PubMed/NCBI
21	Egerer K, Kuckelkorn U, Rudolph PE, Rückert JC, Dörner T, Burmester GR, Kloetzel PM and Feist E: Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol. 29:2045–2052. 2002.PubMed/NCBI
22	Goldberg AL: Functions of the proteasome: The lysis at the end of the tunnel. Science. 268:522–523. 1995. View Article : Google Scholar : PubMed/NCBI
23	Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat. 2:215–223. 1999. View Article : Google Scholar : PubMed/NCBI
24	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
25	Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al: EAU guidelines on prostate cancer. Part. 1:Screening, diagnosis and local treatment with curative intent–update 2013. Eur Urol 65: 124–137. 2014.
26	Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, et al: Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 15:3820–3826. 2009. View Article : Google Scholar : PubMed/NCBI
27	Fowler FJ Jr, Barry MJ, Walker-Corkery B, Caubet JF, Bates DW, Lee JM, Hauser A and McNaughton-Collins M: The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 21:715–721. 2006. View Article : Google Scholar : PubMed/NCBI
28	Deng X, Zhou P, Wei X, Uhlman M, Lin Y, Lin X, Wu S, Diao P, Xie H, Liu J, et al: Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression. Tumour Biol. 36:4115–4121. 2015. View Article : Google Scholar : PubMed/NCBI
29	Frankland-Searby S and Bhaumik SR: The 26S proteasome complex: An attractive target for cancer therapy. Biochim Biophys Acta. 1825:64–76. 2012.PubMed/NCBI
30	Adams J: The proteasome: Structure, function, and role in the cell. Cancer Treat Rev. 29 Suppl 1:S3–S9. 2003. View Article : Google Scholar
31	Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T and Debatin KM: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 91:4624–4631. 1998.PubMed/NCBI
32	Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene. 19:4159–4169. 2000. View Article : Google Scholar : PubMed/NCBI
33	Chen D and Dou QP: The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci. 11:459–470. 2010. View Article : Google Scholar : PubMed/NCBI
34	Almond JB and Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002. View Article : Google Scholar : PubMed/NCBI
35	Li B and Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA. 97:pp. 3850–3855. 2000; View Article : Google Scholar : PubMed/NCBI
36	Kondakova IV, Spirina LV, Koval VD, Shashova EE, Choinzonov EL, Ivanova EV, Kolomiets LA, Chernyshova AL, Slonimskaya EM, Usynin EA and Afanasyev SG: Chymotripsin-like activity and subunit composition of proteasomes in human cancers. Mol Biol (Mosk). 48:444–451. 2014. View Article : Google Scholar : PubMed/NCBI
37	Oldziej A, Bolkun L, Galar M, Kalita J, Ostrowska H, Romaniuk W and Kloczko J: Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leuk Res. 38:925–930. 2014. View Article : Google Scholar : PubMed/NCBI
38	Krawczuk-Rybak M, Leszczynska E, Malinowska I, Matysiak M and Ostrowska H: Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia. Scand J Clin Lab Invest. 72:67–72. 2012. View Article : Google Scholar : PubMed/NCBI